This Department of Defense (DOD) grant is for the rapid implementation of clinical trials designed to significantly impact the treatment or management of multiple sclerosis. The DOD Multiple Sclerosis Clinical Trial Award supports the evaluation of promising new products, including pharmacologic agents (drugs or biologics), medical devices, clinical guidance, and emerging approaches and technologies. Projects can range from small proof-of-concept trials, such as pilot or first-in-human studies, to establish feasibility or inform subsequent designs, up to larger-scale Phase 1 or Phase 2 trials. These larger trials aim to determine the safety or efficacy of interventions within relevant patient populations, ultimately advancing care for individuals with MS.
Opportunity ID: 333436
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-21-MSRP-CTA |
| Funding Opportunity Title: | DOD Multiple Sclerosis Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 10, 2021 |
| Last Updated Date: | May 10, 2021 |
| Original Closing Date for Applications: | Oct 01, 2021 |
| Current Closing Date for Applications: | Oct 01, 2021 |
| Archive Date: | Oct 31, 2021 |
| Estimated Total Program Funding: | $8,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The MSRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0), to demonstrate feasibility or inform the design of more advanced trials, through larger-scale phase 1 or phase 2 trials to determine safety or efficacy in relevant patient populations. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 333436 Full Announcement-FY21 MSRP CTA -> MSRP FY21 CTA PA_GG2.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00267021 | May 10, 2021 | Oct 01, 2021 | View |
Package 1
Mandatory forms
333436 RR_SF424_3_0-3.0.pdf
333436 AttachmentForm_1_2-1.2.pdf
333436 RR_PersonalData_1_2-1.2.pdf
333436 RR_KeyPersonExpanded_3_0-3.0.pdf
333436 RR_Budget_1_4-1.4.pdf
333436 PerformanceSite_3_0-3.0.pdf
Optional forms
333436 RR_SubawardBudget30_1_4-1.4.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
